Iovance Biotherapeutics Inc (IOVA) financials
Iovance Biotherapeutics revenue and earnings by year
Iovance Biotherapeutics's revenue was $264 million in the fiscal year to December 31, 2025, up 60.6% from the year before. Net income was -$391 million, -148.4% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 264 | 164 | 1 |
| Revenue growth | 60.6% | 13699.0% | — |
| Gross profit | 90 | 71 | 0 |
| Gross margin | 34.3% | 43.2% | 13.1% |
| Operating income | -403 | -395 | -461 |
| Operating margin | -153.1% | -240.9% | -38735.0% |
| Net income | -391 | -372 | -444 |
| Net margin | -148.4% | -226.8% | -37345.4% |
| Diluted EPS | -$1.09 | -$1.28 | -$1.89 |
| Free cash flow | -336 | -364 | -384 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open IOVA in Markets.
How Iovance Biotherapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Amtagvi | $90.7M | 91.3% |
| Proleukin | $8.59M | 8.7% |
See also: IOVA returns
No forecast, no recommendation. This page describes Iovance Biotherapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.